GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenovectored product candidates that can deliver on the promise of gene-based medicine.
Our AdenoVerse™ technology platform has been perfected through years of experience translating cutting-edge ideas for disease treatment and prevention into product candidates manufactured under GMP. Our expertise is in designing, constructing and manufacturing novel adenovector-based therapeutics and vaccines. Our proprietary human and nonhuman origin vectors, as well as high-yield cell lines and production techniques, are readily customized for regenerative medicine, cell therapy, and other gene and antigen delivery strategies. Over 3,000 clinical trial subjects have received our therapeutics and vaccines in the U.S., Europe, and Africa; and we have successfully carried out technology transfer campaigns for both pharmaceutical and government partners.
We collaborate with leading companies and organizations to leverage our proprietary technology for the prevention and treatment of significant health concerns. Our pioneering work has ranged from inventing CGF166, our lead product candidate that is now being tested in patients with hearing loss by our partner, Novartis, to working with the Department of Homeland Security and the U.S. Department of Agriculture on the first vaccine against Foot and Mouth Disease in cattle to be licensed for manufacture on the U.S. mainland and allowing a vaccinate-to-live approach. To learn more about GenVec's approach to collaborations and partnerships, click here.